CA
NZ
UK
AU
IND
US
…
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing therapies for rare and serious diseases. Its long-term growth drivers may include successful clinical data readouts, regulatory approvals and partnerships that could support commercialization of its pipeline addressing unmet medical needs. Investors may find the company attractive because positive trial outcomes could materially increase program value in areas with limited treatment options.
Key risks include high probability of clinical or regulatory setbacks, ongoing need for capital to fund development and competition from larger, better-funded peers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -45.58M | -35.75M | -40.33M | -87.97M | -36.86M |
| Net income | -45.62M | -36.18M | -40.33M | -87.50M | -34.51M |
| Selling general administrative | 16.98M | 18.61M | 12.69M | 12.70M | 13.13M |
| Selling and marketing expenses | - | - | 12.30M | - | - |
| Gross profit | - | -0.36M | -0.37M | - | 0.12M |
| Reconciled depreciation | 0.31M | 0.36M | 0.37M | 0.37M | 0.20M |
| Ebit | - | -35.75M | -43.00M | 8.49M | -37.06M |
| Ebitda | -83.25M | -35.39M | -42.63M | 8.87M | -36.87M |
| Depreciation and amortization | - | 0.36M | 0.37M | 0.37M | 0.20M |
| Operating income | -83.25M | -70.58M | -43.00M | 8.49M | -36.87M |
| Other operating expenses | 83.25M | 70.58M | 43.00M | 39.78M | 36.87M |
| Interest expense | - | - | - | 0.46M | 0.20M |
| Tax provision | 0.04M | 0.43M | 0.00M | 0.00M | -2.35M |
| Net interest income | - | - | - | - | 0.00M |
| Income tax expense | 0.04M | 0.43M | - | -0.46M | -2.35M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.12M |
| Total operating expenses | 83.25M | 70.22M | 42.63M | 39.78M | 36.87M |
| Cost of revenue | - | 0.36M | 0.37M | - | - |
| Total other income expense net | 37.67M | 34.82M | 2.67M | -96.46M | 0.01M |
| Net income from continuing ops | -45.62M | -36.18M | -89.08M | -87.97M | -34.51M |
| Net income applicable to common shares | - | - | - | - | -34.51M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 237.60M | 177.41M | 125.89M | 92.79M | 170.55M |
| Intangible assets | 32.39M | 32.39M | 32.39M | 32.39M | 32.39M |
| Other current assets | 1.84M | 3.55M | 5.03M | 3.11M | 3.51M |
| Total liab | 100.82M | 59.27M | 42.48M | 8.61M | 6.55M |
| Total stockholder equity | 136.78M | 118.14M | 83.42M | 84.18M | 164.00M |
| Other current liab | 14.36M | 5.43M | 2.54M | 3.91M | 2.22M |
| Common stock | 0.07M | 0.06M | 0.02M | 0.01M | 0.01M |
| Capital stock | 0.07M | 0.06M | 0.02M | 0.01M | 0.01M |
| Retained earnings | -401.20M | -355.59M | -243.19M | -202.87M | -114.90M |
| Other liab | - | - | - | - | 1.75M |
| Good will | - | - | - | 0.00M | 48.65M |
| Other assets | - | - | - | - | 0.40M |
| Cash | 22.81M | 20.55M | 4.61M | 56.41M | 84.83M |
| Total current liabilities | 18.34M | 11.58M | 3.90M | 6.47M | 4.40M |
| Net debt | -22.17M | -19.59M | -4.23M | -55.66M | -84.06M |
| Short term debt | 0.36M | 0.31M | 0.38M | 0.36M | 0.37M |
| Short long term debt total | 0.64M | 0.95M | 0.38M | 0.75M | 0.77M |
| Other stockholder equity | 482.19M | 417.95M | 326.59M | 287.03M | 278.88M |
| Property plant equipment | - | - | - | - | 0.77M |
| Total current assets | 135.69M | 143.73M | 56.13M | 59.52M | 88.35M |
| Net tangible assets | - | - | - | - | 82.96M |
| Short term investments | 110.53M | 119.63M | 46.49M | - | - |
| Net receivables | 0.51M | - | - | - | - |
| Accounts payable | 3.63M | 5.83M | 0.97M | 2.20M | 1.81M |
| Accumulated other comprehensive income | 0.02M | 0.03M | 0.00M | - | - |
| Non currrent assets other | 68.92M | 0.36M | 0.19M | 0.15M | 0.40M |
| Non current assets total | 101.91M | 33.67M | 69.77M | 33.27M | 82.20M |
| Capital lease obligations | 0.64M | 0.95M | 0.38M | 0.75M | 0.77M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 10.79M | -70.31M | -45.29M | - | 0.00M |
| Change to liabilities | - | - | - | - | 2.14M |
| Total cashflows from investing activities | 10.79M | -70.31M | - | - | - |
| Total cash from financing activities | 53.81M | 133.52M | 33.02M | 0.00M | -0.45M |
| Change to operating activities | - | - | - | - | -2.29M |
| Net income | -45.62M | -36.18M | -40.33M | -87.97M | -34.51M |
| Change in cash | 2.26M | 15.94M | -51.80M | -28.42M | -29.36M |
| Begin period cash flow | 20.55M | 4.61M | 56.41M | 84.83M | 114.19M |
| End period cash flow | 22.81M | 20.55M | 4.61M | 56.41M | 84.83M |
| Total cash from operating activities | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Issuance of capital stock | 53.58M | 133.31M | 33.02M | - | 0.00M |
| Depreciation | 0.31M | 0.36M | 0.37M | 0.37M | 0.20M |
| Other cashflows from financing activities | 53.81M | 0.21M | 0.03M | - | -0.45M |
| Change to netincome | - | - | - | - | 5.55M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 7.65M | 8.71M | -4.92M | 2.37M | -0.15M |
| Stock based compensation | 10.45M | 13.12M | 6.54M | 8.15M | 7.90M |
| Other non cash items | -34.83M | -33.71M | 8.69M | 48.65M | -9.38M |
| Free cash flow | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| ELDN Eledon Pharmaceuticals Inc |
-0.27 8.88% |
2.77 | - | 5.39 | - | 6.82 | 0.84 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc.; and a strategic collaboration with NewcelX Ltd. for the development of the NCEL-101 therapy for Type 1 Diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
| Name | Title | Year Born |
|---|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director | 1972 |
| Dr. Steven N. Perrin Ph.D. | Pres, Chief Scientific Officer & Non Independent Director | 1966 |
| Mr. Paul Sean Little | CFO & Principal Accounting Officer | 1965 |
| Mr. Bryan E. Smith J.D. | Gen. Counsel, Corp. Sec. & Chief Compliance Officer | 1980 |
| Mr. John Herberger | VP of Technical Operations | NA |
| Mr. Gregory J. Flesher | Consultant | 1970 |
| Dr. Jeffrey D. Bornstein | Chief Medical Officer | NA |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer | NA |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director | 1966 |
| Mr. John Herberger | Vice President of Technical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...